Holen Sie sich die Stockscreener-App
2.39
3.69%
0.09
Handel nachbörslich:
2.39
Schlusskurs vom Vortag:
$2.30
Offen:
$2.32
24-Stunden-Volumen:
2.23M
Relative Volume:
0.68
Marktkapitalisierung:
$357.88M
Einnahmen:
$2.82M
Nettoeinkommen (Verlust:
$-114.60M
KGV:
-2.6432
EPS:
-0.9042
Netto-Cashflow:
$-81.94M
1W Leistung:
+0.20%
1M Leistung:
-6.48%
6M Leistung:
-6.48%
1J Leistung:
-17.77%
1-Tages-Spanne:
$2.31
$2.43
1-Wochen-Bereich:
$2.24
$2.585
52-Wochen-Spanne:
$2.01
$5.228
Absci Corp Stock (ABSI) Company Profile
Firmenname
Absci Corp
Sektor
Branche
Telefon
(360) 949-1041
Adresse
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.38 | 345.85M | 2.82M | -114.60M | -81.94M | -0.9042 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.25 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.32 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.55 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.46 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-01-22 | Eingeleitet | Needham | Buy |
| 2024-10-02 | Eingeleitet | Guggenheim | Buy |
| 2024-07-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Eingeleitet | Truist | Buy |
| 2022-03-02 | Fortgesetzt | Cowen | Market Perform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-11-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | BofA Securities | Neutral |
| 2021-08-16 | Eingeleitet | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-16 | Eingeleitet | Stifel | Hold |
Alle ansehen
Absci Corp Aktie (ABSI) Neueste Nachrichten
Absci Highlights AI Antibody Platform, ABS-201 Hair-Loss Trial Milestones at Leerink Conference - Yahoo Finance
Absci's Andreas Busch to Retire as Chief Innovation Officer, to Serve as Scientific Advisor - TradingView
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Absci (ABSI) CFO has 8,307 shares withheld for RSU tax payment - Stock Titan
Absci Corp (ABSI) director Menelas Pangalos buys 75,095 shares in market - Stock Titan
Tax withholding trims Absci (ABSI) CFO Jonasson’s share count - Stock Titan
Absci (ABSI) CEO has 26,761 shares withheld to cover RSU taxes - Stock Titan
Absci Corp. Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer - The Manila Times
Absci names Ransi Somaratne as chief medical officer - Investing.com
Absci names Ransi Somaratne as chief medical officer By Investing.com - Investing.com Canada
Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage - Yahoo Finance
ABSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Activity Recap: Is now the right time to enter Absci Corporation - baoquankhu1.vn
Absci (ABSI) CEO McClain exercises options and withholds shares for taxes - Stock Titan
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026 - The Manila Times
AI drug developer Absci to reveal 2025 results in March webcast - Stock Titan
Absci Corporation (NASDAQ:ABSI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ABSI stock up on initiating dosing in androgenetic alopecia study - MSN
ABSI Technical Analysis & ETF Price Forecast - Intellectia AI
Absci to Participate in Upcoming Investor Conferences - 富途牛牛
AI-driven drug developer Absci lines up four March investor events - Stock Titan
In the Wake of Absci Corporation's (NASDAQ:ABSI) Latest US$75m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble - simplywall.st
Absci (NASDAQ: ABSI) SVP has shares withheld to cover RSU taxes - Stock Titan
OpenAI considers backing AI-led drug discovery firms: report - Seeking Alpha
Absci Corporation: Drawing Potential Insights On ABS-101 And ABS-201 (NASDAQ:ABSI) - Seeking Alpha
What is Absci Corporation’s valuation compared to sectorFed Meeting & Growth Focused Stock Reports - mfd.ru
Absci Corporation (NASDAQ:ABSI) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Sentiment Review: Is Charter Communications Inc stock a buy or sellBull Run & AI Forecasted Entry/Exit Points - baoquankhu1.vn
EPS Watch: Can Absci Corporation lead its sector in growth2025 Volatility Report & Safe Capital Allocation Plans - baoquankhu1.vn
H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Absci Unveils Origin-1 AI Model, Teases 2025 Hair-Loss Data and Q4 Endometriosis Trial Launch - Yahoo Finance
Absci Corp Presents Business Update at J.P. Morgan Healthcare Conference - TradingView
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials - Finviz
10 Best Penny Stocks to Buy for 2026 - Insider Monkey
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Absci (NASDAQ:ABSI) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
How Absci Corporation stock benefits from global expansionEarnings Trend Report & Real-Time Market Trend Scan - ulpravda.ru
Will Absci Corporation stock benefit from commodity pricesJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - Улправда
What dividend safety score for Absci Corporation stockMarket Trend Review & Target Return Focused Picks - Улправда
Published on: 2026-01-08 23:53:06 - ulpravda.ru
Absci (NASDAQ:ABSI) Shares Down 9.1%Here's What Happened - MarketBeat
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile - Investing.com Nigeria
Morgan Stanley Downgrades Absci Corp(ABSI.US) to Hold Rating, Cuts Target Price to $4.32 - 富途牛牛
How resilient is Absci Corporation stock in market downturnsEarnings Miss & AI Optimized Trade Strategies - moha.gov.vn
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates - MSN
Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Absci Corp | 4: Statement of changes in beneficial ownership of securities-Director VAN HOUTEN FRANS - 富途牛牛
Absci Corporation (ABSI) Investor Outlook: Unpacking a 136% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Finanzdaten der Absci Corp-Aktie (ABSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Absci Corp-Aktie (ABSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):